focus -WSS

focus

author：Wikipedia 2025-09-06 04:41:37 - browse：56

Sanofi CEO Paul Hudson Courtesy Sanofi

NEW YORK — The top executives at French drug giant Sanofi on Wednesday defended their decision to reduce earnings forecasts for 2024 in order to fund more research studies of new medicines they say could one day generate billions of dollars in annual sales.

CEO Paul Hudson and Houman Ashrafian, Sanofi’s new head of R&D, made their remarks in an exclusive interview with STAT ahead of a full-day meeting with analysts here. When the cuts to earnings were first announced Oct. 27, along with a plan to spin off the company’s consumer products division, shares dove 18% and have yet to fully recover. The share price is down 5% since the beginning of 2023.

“I’ve been waiting four years for a situation where we could put [out] the pipeline, as impressive as it is, and declare that we’re going to be the world’s leading immunology company,” said Hudson, who took over as CEO in 2019. “So it’s quite an important moment for us. And it’s an important moment to declare that we’re back in science, because I could argue that we haven’t been where we needed to be.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Philips to halt sales of sleep apnea machines in U.S.

hotspot

explore

WSS

Senators push IRS to launch nonprofit hospital probe

Dozens dead from Maui wildfires: What we know about the victims

Novo Nordisk touts Wegovy study, but still struggling with supply

Aspartame and sugar

Why Medicare shouldn’t cover every FDA

Judge sides with young activists in first

focus

focus

entertainment

Novavax promises a turnaround & Lilly roils the obesity market

Illinois Supreme Court finds assault weapons ban constitutional

Alkermes shareholders re

Montana youths win climate lawsuit against state for promoting fossil fuels

Activists slam private health insurers over coverage restrictions

Merck, Johnson & Johnson CEOs will testify on high drug prices

United colonoscopy coverage change 'may cost lives,' doctors say

Illinois Supreme Court finds assault weapons ban constitutional

Supreme Court strikes down use of affirmative action

Illinois Supreme Court finds assault weapons ban constitutional

focus

Bird flu researchers hone in on Finland’s mink farms

Bernie Sanders is gearing up to subpoena pharma CEOs

Judge sides with young activists in first

Aspartame and sugar

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Wegovy leads to weight loss. Can it treat depression, too?

hotspot

explore

focus

focus